# CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

> **NCT04560270** · NA · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 69 (actual)

## Conditions studied

- Pancreatic Cancer
- Circulating Tumor DNA
- KRAS Mutation-Related Tumors

## Interventions

- **DIAGNOSTIC_TEST:** Blood samples

## Key facts

- **NCT ID:** NCT04560270
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-25
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-11-15
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560270, "CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04560270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*